MediWound (NASDAQ:MDWD) Issues Earnings Results, Beats Estimates By $0.23 EPS

by · The Cerbat Gem

MediWound (NASDAQ:MDWD – Get Free Report) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.23, RTT News reports. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. The business had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.79 million. During the same quarter in the previous year, the firm posted ($0.19) EPS.

MediWound Stock Performance

Shares of MDWD stock opened at $18.28 on Thursday. MediWound has a 1 year low of $12.78 and a 1 year high of $24.00. The stock has a fifty day moving average of $18.15 and a two-hundred day moving average of $17.60. The firm has a market capitalization of $197.17 million, a PE ratio of -6.30 and a beta of 0.82.

Analyst Upgrades and Downgrades

MDWD has been the subject of a number of analyst reports. Craig Hallum initiated coverage on MediWound in a research report on Friday, February 28th. They set a “buy” rating and a $39.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of MediWound in a research report on Thursday.

Get Our Latest Stock Report on MediWound

MediWound Company Profile

(Get Free Report)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

Read More